Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA)
India · Delayed Price · Currency is INR 1,758.40
-18.70 (-1.05%)
At close: Mar 23, 2026
Sun Pharmaceutical Industries Employees
Sun Pharmaceutical Industries had 43,000 employees as of March 31, 2025. The number of employees did not change compared to the previous year.
Employees
43,000
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
13.21M INR
Profits / Employee
2.54M INR
Market Cap
4.22T
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2025 | 43,000 | 0 | - |
| Mar 31, 2024 | 43,000 | 2,000 | 4.88% |
| Mar 31, 2023 | 41,000 | 3,000 | 7.89% |
| Mar 31, 2022 | 38,000 | 1,000 | 2.70% |
| Mar 31, 2021 | 37,000 | 1,000 | 2.78% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Cipla | 30,313 |
| Zydus Lifesciences | 27,917 |
| Aurobindo Pharma | 27,707 |
| Mankind Pharma | 19,620 |
| Alkem Laboratories | 18,785 |
| Ipca Laboratories | 16,778 |
| Glenmark Pharmaceuticals | 15,800 |
| Divi's Laboratories | 10,542 |
Sun Pharmaceutical Industries News
- 2 days ago - Domestic companies launch semaglutide jabs at affordable prices - The Times of India
- 2 days ago - Sun Pharma launches Noveltreat and Sematrinity injections in India - Business Upturn
- 6 days ago - Top stocks for trade today, March 17: Reliance Industries, Adani Enterprises, L&T Technology, Sun Pharma and more - Business Upturn
- 7 days ago - Sun Pharma: FDA To Review SBLA For ILUMYA For Treatment Of Adults With Active Psoriatic Arthritis - Nasdaq
- 18 days ago - Bajaj Finance, Havells & more: Top stocks to watch out for on March 6 - The Times of India
- 21 days ago - Nifty 50 top gainers today, March 2: Bharat Electronics, Hindalco Industries, Sun Pharma, ONGC and more - Business Upturn
- 4 weeks ago - UPDATE: Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million - Benzinga
- 4 weeks ago - Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million - Benzinga